Latest filing published 19 Feb 2025 for Keros Therapeutics, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Rovaldi: trading record in brief
Christopher Rovaldi, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Acceleron Pharma Inc and Keros Therapeutics, Inc. We count 19 filings; the first trade dates from 12 September 2017 and the latest from 18 February 2025.
On the market, this insider has only sold: 14 sales, €1.2M in total. Other entries cover 2 share grants and 3 option exercises.
Most recently, on 19 February 2025, the filings show a share grant in Keros Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Christopher Rovaldi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 60,000 shares0Common StockSEC:0001415889-25-004596:0
- 1,728 shares@ US$16.0067.0% of flowCommon StockSEC:0001209191-22-023860:0
- 864 shares@ US$16.0033.0% of flowCommon StockSEC:0001209191-22-023037:0
3 of 3 declarations
